Daxor Corporation reports developments tied to blood volume measurement technology, including commercialization of its FDA-cleared Blood Volume Analysis diagnostics and the BVA-100 Blood Volume Analyzer. Company news commonly covers clinical data, cardiology and critical-care use cases, new customer programs, conference presentations, and product updates for rapid, portable BVA systems.
Daxor also issues updates on financial results, shareholder communications, capital actions, and market expansion for its ezBVA Lab workflow and related diagnostic services. Its coverage centers on precision fluid management, heart failure, ICU care, and adoption of direct blood, plasma, and red-cell volume measurement in clinical settings.
Daxor Corporation (NYSE: DXR) has appointed Caleb DesRosiers to its Board of Directors, effective January 18, 2022. DesRosiers, a Senior Principal at Valuate Healthcare Consultancy, brings extensive strategic and regulatory experience to the role, having previously worked with CMS and in the life sciences sector at Pfizer and Roche. CEO Michael Feldschuh expressed that DesRosiers' expertise will support Daxor's vision of optimal blood volume for patients. Daxor is a leader in blood volume measurement technology with its FDA-cleared BVA-100 Blood Volume Analyzer.
Daxor Corporation (NYSE: DXR) has announced the transfer of its common stock listing from the New York Stock Exchange - American to The Nasdaq Capital Market, effective February 2, 2022. CEO Michael Feldschuh stated that this move is expected to enhance stock visibility, trading liquidity, and attract institutional investors. Daxor is recognized for its BVA-100® technology, the first FDA-cleared diagnostic blood test for quantifying blood volume. The company aims to advance healthcare through optimal fluid management.
Oak Ridge, TN, Jan. 06, 2022 - Daxor, the leader in blood volume measurement technology, announced that CEO Michael Feldschuh will present at the H.C. Wainwright BioConnect 2022 Virtual Conference from January 10-13, 2022. The presentation will be available on-demand starting at 7:00 a.m. ET on January 10. Key highlights will include updates on the new patent award and development of BVA-100. Daxor aims to improve healthcare through advanced blood volume analysis, focusing on enhancing treatment strategies in various medical fields.
Daxor Corporation (NYSE: DXR) announced the completion of patient enrollment and commencement of data analysis for a multi-center observational study utilizing the BVA-100 blood volume measurement technology in hospitalized COVID-19 patients. Conducted by NYU Langone Health and others, the study aims to investigate fluid imbalances in COVID-19 patients, revealing significant capillary damage and blood volume deficits. The results are expected to enhance treatment strategies and outcomes for critically ill patients.
Daxor Corporation (NYSE: DXR) has received a new patent (U.S. Patent No. 11,204,356 B2) for its innovative blood volume analysis technology, aimed at enhancing treatment decisions across various medical conditions. This patent protects a clinical guidance system designed for optimal fluid management, combining unique volume metrics with treatment pathways. CEO Michael Feldschuh emphasized that this marks a significant milestone in advancing healthcare. Daxor is actively developing solutions supported by the National Institutes of Health, aiming to improve outcomes for conditions like heart failure.
Daxor Corporation (NYSE: DXR) presented new studies validating its BVA-100 blood test at the American Heart Association Scientific Sessions. The test helps identify heart failure patient-specific phenotypes and detect true anemia. The first study on patients with left ventricular assist devices revealed blood volume variations, while the second study found traditional hematocrit measures lack sensitivity for true anemia. The findings support the increasing adoption of BVA technology in optimizing heart failure management.
Daxor Corporation (NYSE: DXR) announced significant findings at the NeuroCritical Care Society's 19th Annual Meeting, showcasing the effectiveness of their BVA-100 blood test in managing non-traumatic subarachnoid hemorrhage (nSAH). The study revealed that 69% of physicians altered their treatment strategies based on BVA results, preferring it over invasive methods. Previous studies indicated a 54% change in management and a 66% reduction in ICU mortality linked to BVA tests. These results underscore Daxor's role in improving patient outcomes through enhanced blood volume management.
Daxor Corporation (NYSE: DXR) has been awarded a SBIR/STTR matching fund grant of $200K from Launch Tennessee, linked to a Phase II award from the Department of Defense. This funding will support the development of their next-generation point-of-care blood volume analyzer. The grant is part of a competitive selection aimed at encouraging innovation and job creation in Tennessee, where over 80 applications were received. Daxor's CEO highlighted the importance of this grant for advancing their technology and enhancing patient outcomes.
Daxor Corporation (NYSE: DXR) presented new findings at the Heart Failure Society of America Annual Scientific Meeting 2021, emphasizing the significance of the BVA-100 blood test in managing heart failure. The data illustrated the test's effectiveness in tailoring treatment for patients, especially those with left ventricular assist devices. Notably, studies highlighted improved outcomes for hospitalized patients through blood volume analysis and ultrafiltration techniques. Ongoing clinical trials aim to apply BVA-100 in various settings, enhancing care for over one million heart failure patients in the U.S.
Daxor (NYSE: DXR) will showcase its blood volume measurement technology at the Heart Failure Society of America Annual Scientific Meeting from September 10-13, 2021. The event will feature new clinical trials demonstrating the effectiveness of the BVA-100 test. Daxor's Chief Scientific Officer stated this year’s program is the most comprehensive in the company’s history, highlighting outcomes in patients with left ventricular assist devices and heart failure. The company aims to improve patient outcomes through important clinical studies funded by NIH and the Department of Defense, impacting over 7 million patients in the U.S.